Switch theme
Sign up to access all valuation multiples
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
2006
59
LTM Revenue $52.3M
LTM EBITDA -$51.5M
$467M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Zevra Therapeutics has a last 12-month revenue (LTM) of $52.3M and a last 12-month EBITDA of -$51.5M.
In the most recent fiscal year, Zevra Therapeutics achieved revenue of $23.6M and an EBITDA of -$76.4M.
Zevra Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Zevra Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $52.3M | XXX | $23.6M | XXX | XXX | XXX |
| Gross Profit | $43.2M | XXX | $16.2M | XXX | XXX | XXX |
| Gross Margin | 82% | XXX | 69% | XXX | XXX | XXX |
| EBITDA | -$51.5M | XXX | -$76.4M | XXX | XXX | XXX |
| EBITDA Margin | -98% | XXX | -324% | XXX | XXX | XXX |
| EBIT | -$56.3M | XXX | -$87.0M | XXX | XXX | XXX |
| EBIT Margin | -108% | XXX | -368% | XXX | XXX | XXX |
| Net Profit | -$68.4M | XXX | -$106M | XXX | XXX | XXX |
| Net Margin | -131% | XXX | -447% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $25.7M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Zevra Therapeutics's stock price is $9.
Zevra Therapeutics has current market cap of $468M, and EV of $467M.
See Zevra Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $467M | $468M | XXX | XXX | XXX | XXX | $-1.42 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Zevra Therapeutics has market cap of $468M and EV of $467M.
Zevra Therapeutics's trades at 19.8x EV/Revenue multiple, and -6.1x EV/EBITDA.
Equity research analysts estimate Zevra Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Zevra Therapeutics has a P/E ratio of -6.8x.
See valuation multiples for Zevra Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $468M | XXX | $468M | XXX | XXX | XXX |
| EV (current) | $467M | XXX | $467M | XXX | XXX | XXX |
| EV/Revenue | 8.9x | XXX | 19.8x | XXX | XXX | XXX |
| EV/EBITDA | -9.1x | XXX | -6.1x | XXX | XXX | XXX |
| EV/EBIT | -8.3x | XXX | -5.4x | XXX | XXX | XXX |
| EV/Gross Profit | 10.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | -6.8x | XXX | -4.4x | XXX | XXX | XXX |
| EV/FCF | 53.0x | XXX | -6.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialZevra Therapeutics's last 12 month revenue growth is 131%
Zevra Therapeutics's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $1.7M for the same period.
Zevra Therapeutics's rule of 40 is -27% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Zevra Therapeutics's rule of X is 230% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Zevra Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 131% | XXX | 161% | XXX | XXX | XXX |
| EBITDA Margin | -98% | XXX | -324% | XXX | XXX | XXX |
| EBITDA Growth | -95% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -27% | XXX | -192% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 230% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 178% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 437% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Zevra Therapeutics acquired XXX companies to date.
Last acquisition by Zevra Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Zevra Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Zevra Therapeutics founded? | Zevra Therapeutics was founded in 2006. |
| Where is Zevra Therapeutics headquartered? | Zevra Therapeutics is headquartered in United States of America. |
| How many employees does Zevra Therapeutics have? | As of today, Zevra Therapeutics has 59 employees. |
| Who is the CEO of Zevra Therapeutics? | Zevra Therapeutics's CEO is Mr. Neil F. McFarlane, M.S.. |
| Is Zevra Therapeutics publicy listed? | Yes, Zevra Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Zevra Therapeutics? | Zevra Therapeutics trades under ZVRA ticker. |
| When did Zevra Therapeutics go public? | Zevra Therapeutics went public in 2015. |
| Who are competitors of Zevra Therapeutics? | Similar companies to Zevra Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Zevra Therapeutics? | Zevra Therapeutics's current market cap is $468M |
| What is the current revenue of Zevra Therapeutics? | Zevra Therapeutics's last 12 months revenue is $52.3M. |
| What is the current revenue growth of Zevra Therapeutics? | Zevra Therapeutics revenue growth (NTM/LTM) is 131%. |
| What is the current EV/Revenue multiple of Zevra Therapeutics? | Current revenue multiple of Zevra Therapeutics is 8.9x. |
| Is Zevra Therapeutics profitable? | Yes, Zevra Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Zevra Therapeutics? | Zevra Therapeutics's last 12 months EBITDA is -$51.5M. |
| What is Zevra Therapeutics's EBITDA margin? | Zevra Therapeutics's last 12 months EBITDA margin is -98%. |
| What is the current EV/EBITDA multiple of Zevra Therapeutics? | Current EBITDA multiple of Zevra Therapeutics is -9.1x. |
| What is the current FCF of Zevra Therapeutics? | Zevra Therapeutics's last 12 months FCF is $8.8M. |
| What is Zevra Therapeutics's FCF margin? | Zevra Therapeutics's last 12 months FCF margin is 17%. |
| What is the current EV/FCF multiple of Zevra Therapeutics? | Current FCF multiple of Zevra Therapeutics is 53.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
